CHILDREN'S CANCER GROUP

费城儿童医院为这一科学做出了贡献 儿童癌症组织在过去25年中的患者情况 参加学习，在委员会和战略小组中担任科学领导， 以及试点研究的启动和实施。特定的 主要贡献如下：1)使用骨髓移植 神经母细胞瘤大剂量强化治疗后；2)进展 将纳入神经肿瘤学的临床和生物学研究 进入随机分组试验；3)启动一种实施方法 利用随机数字拨号技术进行的流行病学研究 视网膜母细胞瘤、脑肿瘤与父母职业的团体研究 通过资助赠款；4)在开发方面提供领导和专业知识 癌症治疗的远期效应研究；以及5)对 白血病、霍奇金氏病、淋巴瘤、横纹肌肉瘤和脑瘤 担任集团的早期飞行员。参与调查的调查人员 这一努力将继续为患者提供高质量的数据 在基础科学领域开始学习和领导，最近 治疗效果、神经肿瘤学、骨髓移植、生物学 反应调节剂和病因学及预防。100多名患者 每年都被CHOP及其附属公司纳入CCG研究-- 威尔明顿医疗中心、盖辛格医疗中心和艾伯特 爱因斯坦医院，有1000多人正在接受跟踪研究；它是 预计未来随着研究的深入，这一数字将会增加 目前无法获得的疾病被发起。印章调查员现在担任主席 主要策略组(ANL、淋巴瘤和软组织肉瘤)和 在所有研究领域提供委员会领导。有23个 该机构的调查人员担任108个研究职位 委员会、战略小组或科学委员会，其中20个在 担任领导职务。我们将继续招募所有符合条件的患者 并且为了符合关于学习参与的团体要求， 除在上述具体领域发挥领导作用外，还将在其他领域发挥领导作用。

The Children's Hospital of Philadelphia has contributed to the science of the Childrens Cancer Group in the last 25 years with regard to patient entry on study, scientific leadership in committees and strategy groups, and the initiation and performance of pilot studies. Specific contributions have been the following: 1) Use of bone marrow transplant following high dose intensive therapy for neuroblastoma; 2) Development of clinical and biology studies in neuro-oncology that will be incorporated into randomized Group trials; 3) Initiation of a method of performing epidemiologic studies utilizing the random-digit dialing technique in Group studies of retinoblastoma, brain tumors and parental occupation through funded grants; 4) Providing leadership and expertise in developing studies of late effects of cancer therapy; and 5) Performing studies for leukemia, Hodgkin's disease, lymphomas, rhabdomyosarcoma, and brain tumors serving as early pilots for the Group. The investigators participating in this endeavor will continue to provide data of high quality for patients entered on study as well as leadership in the areas of basic science, late effects of therapy, neuro-oncology, bone marrow transplantation, biologic response modifiers and etiology and prevention. More than 100 patients have been entered on CCG studies annually from CHOP and its affiliates -- the Wilmington Medical Center, Geisinger Medical Center and Albert Einstein Hospital, and more than 1,000 are being followed on study; it is expected that this number will increase in the future as studies for diseases not now available are initiated. CHOP investigators now chair major Strategy Groups (ANL, Lymphoma and Soft Tissue Sarcoma) and are providing committee leadership in all areas of study. There are 23 investigators in this institution holding 108 positions on study committees, strategy groups, or scientific committees, 20 of them being in positions of leadership. We will continue to enroll all eligible patients and to conform to group requirements with regard to study participation, in addition to providing leadership in the specific areas noted above.